Pre-Tax Income: Company's earnings or loss before taxes on income have been accounted for.
ImmunityBio, Inc. (IBRX) had Pre-Tax Income of $-632.79M for the most recently reported fiscal quarter, ending 2026-03-31.
| Income Statement Financials | |
$44.21M |
|
$-632.78M |
|
$0.24M |
|
$43.97M |
|
$114.00M |
|
$-69.79M |
|
$-563.00M |
|
|
Pre-Tax Income |
$-632.79M |
$-632.79M |
|
$-632.80M |
|
$-632.80M |
|
$-632.80M |
|
$-632.80M |
|
$-69.79M |
|
$-66.94M |
|
1.03B |
|
1.03B |
|
$-0.62 |
|
$-0.62 |
|
| Balance Sheet Financials | |
$452.95M |
|
$112.78M |
|
$193.68M |
|
$646.64M |
|
$67.95M |
|
$678.39M |
|
$1.45B |
|
$1.52B |
|
$-869.13M |
|
$-882.01M |
|
$-869.13M |
|
1.05B |
|
| Cash Flow Statement Financials | |
$-75.36M |
|
$-31.65M |
|
$223.93M |
|
$89.43M |
|
$206.47M |
|
$117.04M |
|
$8.17M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
6.67 |
|
-- |
|
-- |
|
-3.56 |
|
-0.78 |
|
99.46% |
|
-157.88% |
|
-157.88% |
|
-- |
|
-1431.45% |
|
-1431.44% |
|
$-77.14M |
|
-- |
|
-- |
|
-- |
|
0.07 |
|
0.44 |
|
1.02 |
|
88.10 |
|
72.81% |
|
71.74% |
|
-97.86% |
|
331.76% |
|
$-0.83 |
|
$-0.08 |
|
$-0.07 |
|